Batu Biologics Announces FDA Development Plans For ValloVax Angiogenesis-Targeting Cancer Vaccine
Published: Jun 09, 2014
SAN DIEGO--(BUSINESS WIRE)--Batu Biologics announced today FDA development plans for its patent-pending lead product, ValloVax™, a cancer immunotherapeutic “vaccine” that specifically targets the tumor blood vessels (endothelium). The vaccine is a “therapeutic vaccine” in that it will be used to stimulate the immune system of patients that already suffer from cancer. This is in contrast to conventional vaccines which are prophylactic, meaning that they are administered to prevent onset of disease.
Help employers find you! Check out all the jobs and post your resume.